JAK2 and neoplasm: JAK2 inhibitors can transiently mask the intracellular signaling of the cytokine and the resulting toxicity, de facto creating a rapid and reversible pharmacological ON/OFF switch that localizes the activity of the payload to the tumor site while sparing healthy tissues (Fig. 1A).